Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Bart A. Nijmeijer"'
Autor:
Roni F. Kunst, Isabelle Bolt, Rychon D.J. van Dasselaar, Bart A. Nijmeijer, Ulrich Beuers, Ronald P.J. Oude Elferink, Stan F.J. van de Graaf
Publikováno v:
JHEP Reports, Vol 6, Iss 1, Pp 100917- (2024)
Background & Aims: Intestine-restricted inhibitors of the apical sodium-dependent bile acid transporter (ASBT, or ileal bile acid transporter) are approved as treatment for several inheritable forms of cholestasis but are also associated with abdomin
Externí odkaz:
https://doaj.org/article/9b3c1ec91c60416aac41d256534c3c20
Autor:
Christian F. Meyer, Bart A. Nijmeijer, Valerie Ferreira, Martin de Haan, Margit H. Lampen, Anna Majowicz, Marco Tangelder, Lisa Spronck, Harald Petry, Sander J. H. van Deventer
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Currently, individuals with pre-existing neutralizing antibodies (NABs) against adeno-associated virus (AAV) above titer of 5 are excluded from systemic AAV-based clinical trials. In this study we explored the impact of pre-existing anti-AAV5 NABs on
Autor:
Susanne Badura, Tamara Tesanovic, Heike Pfeifer, Sylvia Wystub, Bart A Nijmeijer, Marcus Liebermann, J H Frederik Falkenburg, Martin Ruthardt, Oliver G Ottmann
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80070 (2013)
PurposeAberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase
Externí odkaz:
https://doaj.org/article/8be4fcff685f4559b7a75dabb1fd3081
Autor:
Paula S Montenegro-Miranda, Valerie Ferreira, Harald Petry, Elisabeth A. Spronck, Sander J. H. van Deventer, Bart A. Nijmeijer, Erich Ehlert, Sander Gielen, Jacek Lubelski, Ying Poi Liu, Martin de Haan
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss, Pp 221-231 (2019)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy-Methods and Clinical Development, 15, 221-231. CELL PRESS
Molecular Therapy. Methods & Clinical Development
Molecular Therapy-Methods and Clinical Development, 15, 221-231. CELL PRESS
Gene therapy for severe hemophilia B is advancing and offers sustained disease amelioration with a single treatment. We have reported the efficacy and safety of AMT-060, an investigational gene therapy comprising an adeno-associated virus serotype 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b4294973adf70abce05445843ac809
https://doi.org/10.1016/j.omtm.2019.09.005
https://doi.org/10.1016/j.omtm.2019.09.005
Autor:
Bart A. Nijmeijer, Bas Bosma, Harald Petry, Jacek Lubelski, Martin de Haan, Erich Ehlert, Francois du Plessis
Publikováno v:
Gene Therapy. 25:415-424
Recombinant adeno-associated virus (rAAV) has become the vector of choice for the development of novel human gene therapies. High-yield manufacturing of high-quality vectors can be achieved using the baculovirus expression vector system. However, eff
Autor:
Bart A. Nijmeijer, Inge Jedema, J.H. Frederik Falkenburg, Floris C. Loeff, H. M. Esther van Egmond, Constantijn J.M. Halkes
Publikováno v:
Leukemia & Lymphoma
Leukemia & Lymphoma, 58(9), 2185-2195
Leukemia & Lymphoma, 58(9), 2185-2195
To optimally utilize therapeutic monoclonal antibodies in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) understanding their mechanisms of action and the factors influencing these mechanisms is required. We show strong correlations betw
Autor:
Saskia Maas, Marieke Griffioen, Bart A. Nijmeijer, Marianke L.J. van Schie, Daniela C.F. Salvatori, Sanja Stevanović, J.H. Frederik Falkenburg
Publikováno v:
Biology of Blood and Marrow Transplantation, 19(6), 867-875
Alloreactive (allo)-HLA–directed T cell responses after HLA-mismatched allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion are typically considered detrimental responses mediating graft-versus-host disease (GVHD). Allo-
Autor:
Fabio Ciceri, Bart A. Nijmeijer, Zohara Aghai, Claudio Bordignon, Lothar Hambach, Marina Radrizzani, Attilio Bondanza, Katharina Fleischhauer, Shin Kaneko, Sara Mastaglio, Els Goulmy, Chiara Bonini
Publikováno v:
Blood, 117(24), 6469-78
Blood, 117(24), 6469-6478
Blood, 117(24), 6469-6478
In allogeneic hematopoietic cell transplantation (HSCT), donor T lymphocytes mediate the graft-versus-leukemia (GVL) effect, but induce graft-versus-host disease (GVHD). Suicide gene therapy—that is, the genetic induction of a conditional suicide p
Autor:
Erik W.A. Marijt, H. M. Goselink, Marja van der Burg, Karoly Szuhai, Oliver G. Ottmann, Danielle de Jong, Bart A. Nijmeijer, J.H. Frederik Falkenburg, Roel Willemze, Marianke L.J. van Schie
Publikováno v:
Experimental Hematology. 37:376-385
Objective B–lineage acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia in lymphatic blastic phase in adults have poor prognoses despite intensive chemotherapy. Novel targeted treatment modalities emerge, but their evaluation requires r
Autor:
Henk-Jan Guchelaar, Bart A. Nijmeijer, Kirsten J. M. Schimmel, J.H. Frederik Falkenburg, Marianke L.J. van Schie
Publikováno v:
Leukemia Research. 31:1545-1551
The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is a non-competitive inhibitor of the enzyme cytidine triphosphate (CTP) synthethase. We evaluated the in vitro and in vivo antitumor activity of CPEC on human acute lymphoblastic leukemia